Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P36269

UPID:
GGT5_HUMAN

ALTERNATIVE NAMES:
Gamma-glutamyl transpeptidase-related enzyme; Gamma-glutamyltransferase 5; Gamma-glutamyltransferase-like activity 1; Gamma-glutamyltranspeptidase 5; Leukotriene-C4 hydrolase

ALTERNATIVE UPACC:
P36269; Q53XM9; Q6GMP0; Q96FC1; Q9UFM5

BACKGROUND:
The enzyme Gamma-glutamyltransferase 5, with alternative names such as Gamma-glutamyl transpeptidase-related enzyme and Leukotriene-C4 hydrolase, is integral to glutathione metabolism. It specifically cleaves glutathione and glutathione-S-conjugates, playing a key role in detoxifying harmful compounds. Furthermore, it regulates geranylgeranyl glutathione's bioactivity, implicating its significance in adaptive immune responses.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Gamma-glutamyltransferase 5 reveals its potential in developing novel therapeutic approaches. Its critical role in modulating immune responses and detoxification pathways positions it as a promising target for interventions in immune-related disorders and conditions associated with oxidative damage.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.